NEWARK, Calif., Aug. 12, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that it has strengthened its leadership team with the appointment of Arthur P. Bertolino as Executive Vice President and Chief Medical Officer. Dr. Bertolino, a Board Certified dermatologist and seasoned dermatology industry executive, joins Revance on September 2 with nearly 30 years of experience, including more than 13 years in global biotechnology and pharmaceutical drug development. In addition, he has substantial clinical and regulatory experience across dermatology, including hyperhidrosis, psoriasis, and hair growth.
Dr. Bertolino is highly regarded for his international clinical research and development. He most recently served as Vice President of Dermatology for Novartis Institutes for Biomedical Research (NIBR). Prior, he was the Vice President & Global Head of Translational Medicine for Autoimmunity, Immunology and Dermatology at NIBR. During his tenure with NIBR, he drove all early stage clinical and supportive regulatory activities for submission in therapy areas, including small molecules, biologics, and cell-based therapies. Prior to joining Novartis, he was Chief Medical Officer and Vice President, Medical Affairs, for Peplin, Inc., and Senior Director, Dermatology, for Pfizer.
"Art's depth of clinical and regulatory experience, ranging from therapeutic drug development to dermatology, is an excellent fit for Revance," said President and Chief Executive Officer, Dan Browne. "His scientific and clinical leadership capabilities have been proven in both large and emerging pharmaceutical companies. Under his leadership I am confident that he will enhance our initiatives to leverage our proprietary TransMTS® peptide technology across multiple indications and dose forms. I look forward to working closely with him as we move our botulinum toxin product candidates through clinical trials, regulatory approvals and towards commercialization."
"I am delighted to be joining Revance at this stage of its growth and look forward to advancing the development of Revance's RT001 topical and RT002 injectable product candidates," said Dr. Bertolino. "Being a part of this unique neurotoxin opportunity and having the opportunity to build upon the remarkable scientific and clinical data generated to date, I look forward to making a meaningful impact on the future of Revance."
Dr. Bertolino received his M.D. and Ph.D. at The Johns Hopkins University School of Medicine and his post-graduate training at the NYU School of Medicine. He has an M.B.A. from the University of Michigan - Stephen M. Ross School of Business. Dr. Bertolino has been an author on over 50 abstracts, manuscripts and book chapters, and a contributor to numerous national consumer publications, including Allure, Elle, GQ, Good Housekeeping, Self and many others.
About Revance Therapeutics, Inc.
Revance is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. Revance is leveraging its proprietary portfolio of botulinum toxin compounds combined with its patented TransMTS® peptide delivery system to address unmet needs in the large and growing aesthetic and therapeutic botulinum toxin market. Revance's proprietary TransMTS® technology enables transcutaneous delivery of botulinum toxin A, eliminating the need for injections. Revance's lead product candidate, RT001, is a topical formulation of botulinum toxin type A, which has the potential to be the first commercially-available non-injectable dose form. RT001 is being evaluated in a broad clinical program that includes aesthetic indications such as crow's feet lines (wrinkles around the eyes) and therapeutic indications such as hyperhidrosis (excessive sweating) and migraine headache. Revance's second product candidate is RT002, a novel injectable formulation of botulinum toxin type A designed to be more targeted and longer lasting than currently available botulinum toxin injectable products.
"Revance Therapeutics", TransMTS® and the Revance logo are registered trademarks of Revance Therapeutics, Inc.
For more information, please visit: www.revance.com.
CONTACT: Westwicke Partners Leigh Salvo (415) 513-1281 email@example.comSource:Revance Therapeutics, Inc.